181
Participants
Start Date
December 2, 2020
Primary Completion Date
May 25, 2021
Study Completion Date
May 25, 2021
BGB-DXP593
Intravenous (IV) infusion administered over 30 to 90 minutes at a dose as specified in the treatment arm
Placebo
Placebo to match BGB-DXP593 administered as specified in the treatment arm
Task Clinical Research Centre, Cape Town
Langeberg Clinical Trials, Cape Town
Hospital Cardiologica Aguascalientes, Aguascalientes
Btc Network Midland Florida Clinical Research Center, DeLand
Orlando Health Ufhealth Cancer Center, Orlando
Elixia Clinical Research Collaborative, Hollywood
Homestead Associates in Research Inc, Miami
Medical Research Center of Miami Ii, Inc, Miami
Us Associates in Research, Miami
Continental Research Network, Miami
Revive Research Institute, Dearborn
Revival Research Institute Farmington Hills, Sterling Heights
IECSI, Monterrey
Panamerican Clinical Research Us Headquarters, Brownsville
Amarillo Center For Clinical Research, Amarillo
Hospital Das Clinicas Da Faculdade de Medicina de Botucatu, Botucatu
Fundacao Universidade de Caxias Do Sul, Caxias do Sul
Consultoria Medica E Pesquisa Clinica, Sorcaba
Lead Sponsor
BeiGene
INDUSTRY